RESUMO
Aim To evaluate whether the combination of polypeptide AP25 and docetaxel is more efficient in treating experimental breast cancer,than either reagent used alone,and to offer suggestions for clinical use. Methods An experimental breast carcinoma model was set up to investigate the anti-tumor effects of AP25 and docetaxel combination.The Q value was caluculat-ed by Guinness rules and the anti-tumor effects of the combination of polypeptide AP25 and docetaxel were e-valuated.Results The treatment by the combination of polypeptide AP25 and docetaxel showed a better tumor inhibition rate.The combination of AP25 20 mg ·kg -1 and docetaxel 10 mg·kg -1 significantly inhibi-ted the tumor growth with 0.85 1.15,showing a synergistic effect.Conclusions The combination of AP25 and docetaxel can significantly in-hibit the tumor growth with a synergistic effect and de-crease the dose of chemotherapy.
RESUMO
@#mPEG-SC20k-HM-3 is a novel anti-angiogenesis peptide with integrin affinity. To investigate the anti-tumor activities of mPEG-SC20k-HM-3 and oxaliplatin(OXA)combination, a transplanted tumor model of human hepatocellular carcinoma SMMC-7721 in nude mice was established. Jin′s formula to evaluate the combination effect was used. Data suggested that the anti-tumor activities of combined groups were better than those of single drug(P< 0. 05). Inhibition rate of group 8(OXA 7. 5 mg/kg and mPEG-SC20k-HM-3 73. 4 mg/kg)was 84. 6%, which showed remarkable superiority to group 3(OXA 7. 5 mg/kg)and group 4(mPEG-SC20k-HM-3 73. 4 mg/kg). The Q of group 8 was 1. 164(> 1. 15). This combination had synergistic effect. Combination of mPEG-SC20k-HM-3 and oxaliplatin is a method of inhibiting hepatocellular carcinoma.